x4 pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and reverse immune suppression, which is fundamental to treating cancer and certain rare, genetic primary immunodeficiency diseases. our oral, small molecule drug candidates inhibit the binding of chemokine cxcl12 to c-x-c receptor type 4 (cxcr4), a receptor-ligand pair that plays an essential role in normal immune surveillance. we are committed to advancing the fields of cancer immunotherapy and genetic immune disorders through innovation and investment in our proprietary clinical and preclinical pipeline. x4’s most advanced product candidate, x4p-001-rd, is in a phase 2/3 study in patients with whim syndrome, a rare genetic, primary immunodeficiency disease. x4p-001-io is currently under investigation in multiple phase 1/2 studies in refractory clear cell renal cell carcinoma (ccrcc) and melanoma. our third program, x4p-002, is in preclinical development and designed specifically for the t
Company profile
Ticker
XFOR, XFOWW, XFORW
Exchange
Website
CEO
Paula Ragan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Arsanis, Inc.
SEC CIK
Corporate docs
Subsidiaries
X4 Pharmaceuticals (Austria) GmbH • X4 Pharmaceuticals Securities Corporation • X4 Therapeutics Inc. ...
XFOR stock data
Latest filings (excl ownership)
8-K
Other Events
5 Apr 24
8-K
Regulation FD Disclosure
1 Apr 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial
21 Mar 24
S-8
Registration of securities for employees
25 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Regulation FD Disclosure
27 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
14 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
9 Nov 23
Transcripts
XFOR
Earnings call transcript
2023 Q4
21 Mar 24
XFOR
Earnings call transcript
2023 Q3
9 Nov 23
XFOR
Earnings call transcript
2023 Q2
10 Aug 23
XFOR
Earnings call transcript
2023 Q1
4 May 23
XFOR
Earnings call transcript
2023 Q1
4 May 23
XFOR
Earnings call transcript
2022 Q4
21 Mar 23
XFOR
Earnings call transcript
2022 Q3
3 Nov 22
XFOR
Earnings call transcript
2022 Q2
7 Aug 22
XFOR
Earnings call transcript
2022 Q1
12 May 22
XFOR
Earnings call transcript
2021 Q4
17 Mar 22
Latest ownership filings
4
Arthur Taveras
11 Mar 24
4
Paula Ragan
11 Mar 24
4
Adam S. Mostafa
11 Mar 24
4
Mary DiBiase
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
4/A
Christophe Arbet-Engels
28 Feb 24
4
Christophe Arbet-Engels
16 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 132.60 mm | 132.60 mm | 132.60 mm | 132.60 mm | 132.60 mm | 132.60 mm |
Cash burn (monthly) | 1.62 mm | (no burn) | 9.07 mm | 11.78 mm | 22.93 mm | 13.53 mm |
Cash used (since last report) | 11.13 mm | n/a | 62.43 mm | 81.03 mm | 157.82 mm | 93.08 mm |
Cash remaining | 121.47 mm | n/a | 70.18 mm | 51.57 mm | -25.21 mm | 39.53 mm |
Runway (months of cash) | 75.1 | n/a | 7.7 | 4.4 | -1.1 | 2.9 |
Institutional ownership, Q3 2023
90.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 96 |
Opened positions | 8 |
Closed positions | 16 |
Increased positions | 28 |
Reduced positions | 26 |
13F shares | Current |
---|---|
Total value | 121.99 bn |
Total shares | 152.59 mm |
Total puts | 163.90 k |
Total calls | 97.20 k |
Total put/call ratio | 1.7 |
Largest owners | Shares | Value |
---|---|---|
Bain Capital Life Sciences Investors | 15.96 mm | $17.40 bn |
Growth Equity Opportunities 18 VGE | 15.74 mm | $30.54 mm |
NEA Management | 14.99 mm | $16.34 bn |
Bain Capital Life Sciences Fund | 12.20 mm | $0.00 |
BLK Blackrock | 8.16 mm | $8.89 bn |
Vanguard | 7.82 mm | $8.53 bn |
Polar Capital | 7.50 mm | $8.18 bn |
Orbimed Advisors | 7.13 mm | $7.78 bn |
Tri Locum Partners | 6.25 mm | $6.81 bn |
Empery Asset Management | 6.20 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Mar 24 | Mostafa Adam S. | Common Stock | Sell | Dispose S | No | No | 0.8828 | 52,500 | 46.35 k | 0 |
11 Mar 24 | Arthur Taveras | Common Stock | Sell | Dispose S | No | No | 0.8818 | 14,235 | 12.55 k | 234,301 |
11 Mar 24 | Ragan Paula | Common Stock | Sell | Dispose S | No | No | 0.8828 | 49,678 | 43.86 k | 765,068 |
11 Mar 24 | Mary DiBiase | Common Stock | Sell | Dispose S | No | No | 0.882 | 15,409 | 13.59 k | 291,752 |
13 Feb 24 | Arbet-Engels Christophe | Stock Appreciation Right Common Stock | Grant | Acquire A | No | No | 0.921 | 475,831 | 438.24 k | 475,831 |
News
HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $3 Price Target
22 Mar 24
12 Health Care Stocks Moving In Thursday's Intraday Session
21 Mar 24
Earnings Scheduled For March 21, 2024
21 Mar 24
Recap: X4 Pharmaceuticals Q4 Earnings
21 Mar 24
X4 Pharmaceuticals Q4 EPS $(0.10) Beats $(0.15) Estimate
21 Mar 24
Press releases
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 Apr 24
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
21 Mar 24
Thinking about buying stock in Marpai, Axcelis Technologies, Amylyx Pharmaceuticals, Biomx, or X4 Pharmaceuticals?
11 Mar 24
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 Mar 24